Related Experiment Video
Updated: Jun 20, 2026
04:36
Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery
Published on: April 14, 2026
[Vitreous substitutes as drug release systems]
P Szurman1, C Frank, R T Kaczmarek
1Universitäts-Augenklinik, Department für Augenheilkunde, Eberhard-Karls-Universität, Tübingen. peter.szurman@med.unituebingen.de
Klinische Monatsblatter Fur Augenheilkunde
|September 15, 2009
Summary
New vitreous substitutes offer sustained drug delivery to treat proliferative vitreoretinopathy (PVR). These slow-release systems, including polymerised hydrogels, aim to improve surgical outcomes for retinal scarring and cell proliferation.
Area of Science:
- Ophthalmology
- Biomaterials Science
Context:
- Proliferative vitreoretinopathy (PVR) remains a significant challenge in vitreo-retinal surgery despite advancements.
- Standard surgical techniques may be insufficient for complex PVR cases, necessitating adjuvant therapies.
Purpose:
- To review recent developments in slow-release intravitreal drug delivery systems.
- To explore vitreous substitutes that can also function as drug-eluting platforms for PVR treatment.
Summary:
- Intravitreal slow-release systems are desirable for delivering anti-proliferative and anti-inflammatory drugs due to their narrow therapeutic range and short half-life.
- Vitreous substitutes that double as slow-release systems offer advantages for PVR management.
- Developments include polymerised hydrogels and modified standard tamponades (silicone oils, gases) for extended drug delivery over weeks.
Impact:
- Potential to enhance the efficacy of PVR treatment by providing sustained pharmacological support.
- Offers a promising therapeutic approach combining surgical intervention with controlled drug release.
- May lead to improved patient outcomes by suppressing retinal cell proliferation and scarring.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...